- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.09. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Guard Therapeutics International AB | 301 | GlobeNewswire | With effect from September 05, 2024, the subscription rights in Guard
Therapeutics International AB will be traded on First North Growth Market.
Trading will continue up until and including September... ► Artikel lesen | |
| 02.09. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024 | 425 | Xetra Newsboard | Das Instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024 The instrument MSPA MA0000011488 ITISSALAT AL-MA.... ► Artikel lesen | |
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 29.08. | Guard Therapeutics International AB: First patient dosed in Guard Therapeutics' phase 2b study POINTER | 154 | GlobeNewswire (Europe) | Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
"It... ► Artikel lesen | |
| 27.08. | Guard Therapeutics International AB: Guard Therapeutics carries out announced rights issue (repair issue) | 104 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 54,34 | +0,59 % | Novonesis (Novozymes A/S): Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% | Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance... ► Artikel lesen | |
| GENMAB | 195,15 | +0,44 % | Genmab A/S: Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | Results from Arm 1 of the EPCORE NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,070 | -0,13 % | Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B | Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,450 | 0,00 % | Moleculin Biotech, Inc. - 8-K, Current Report | ||
| VERICEL | 52,50 | -3,67 % | Vericel Corporation: Vericel Reports Third Quarter 2024 Financial Results | Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,414 | -3,50 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,830 | -0,48 % | MustGrow Biologics Corp.: MustGrow Biologics Announces Proposed Private Placement of Units for Approximately $2 Million | Saskatoon, Saskatchewan--(Newsfile Corp. - December 11, 2024) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a proposed non-brokered... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,314 | -3,14 % | BioXcel Therapeutics stock hits 52-week low at $0.35 | ||
| REGENXBIO | 7,000 | -4,11 % | REGENXBIO Inc.: REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates | Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this... ► Artikel lesen | |
| AKEBIA | 1,696 | -3,64 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025
Over 300,000 patients, representing approximately 60% of dialysis patient... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 5,650 | -1,74 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales | ~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 2,940 | -0,68 % | Revance Therapeutics ticks higher as holder says Crown deal undervalues company | ||
| ZEVRA THERAPEUTICS | 8,250 | +1,23 % | Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 | CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 5,010 | +14,51 % | Aktien New York Ausblick: Vorsichtiger Optimismus vor US-Leitzinsentscheidung | NEW YORK (dpa-AFX) - Am US-Aktienmarkt zeichnen sich am Mittwoch zum Handelsstart moderate Gewinne ab. Im Fokus steht die Leitzinsentscheidung zwei Stunden vor Börsenschluss und die begleitenden Kommentare... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 19,000 | +21,79 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment... ► Artikel lesen |
Das Unternehmen GUARD THERAPEUTICS INTERNATIONAL AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,520 Euro und damit -0,65 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.
